A Phase I, Randomized, Single-Blinded, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of MOD-6031 in Healthy Volunteers

Trial Profile

A Phase I, Randomized, Single-Blinded, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of MOD-6031 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2016

At a glance

  • Drugs Oxyntomodulin (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors OPKO Health
  • Most Recent Events

    • 07 Nov 2016 According to an OPKO Health media release, safety data from this trial expected early 2017.
    • 17 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
    • 17 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top